Samjo Management LLC Sells 192,244 Shares of MDxHealth SA $MDXH

Key Points

• Samjo Management LLC cut its stake in MDxHealth SA by 10.5%, now holding 1,632,068 shares valued at approximately $2.32 million.
• Several institutional investors, including AWM Investment Company and Perkins Capital Management, have recently adjusted their holdings, with AWM increasing its stake by 11.1%.
• MDxHealth reported earnings of ($0.15) per share, missing estimates, and aims for Q2 2025 guidance of -0.150--0.150 EPS.

Samjo Management LLC cut its holdings in MDxHealth SA (NASDAQ:MDXH - Free Report) by 10.5% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,632,068 shares of the company's stock after selling 192,244 shares during the period. MDxHealth accounts for approximately 1.0% of Samjo Management LLC's portfolio, making the stock its 27th biggest holding. Samjo Management LLC owned 3.45% of MDxHealth worth $2,318,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in MDXH. Perkins Capital Management Inc. grew its position in MDxHealth by 20.1% during the first quarter. Perkins Capital Management Inc. now owns 1,181,475 shares of the company's stock worth $1,678,000 after buying an additional 198,000 shares in the last quarter. Castleview Partners LLC acquired a new stake in MDxHealth during the first quarter worth about $48,000. AWM Investment Company Inc. grew its position in MDxHealth by 11.1% during the fourth quarter. AWM Investment Company Inc. now owns 4,721,290 shares of the company's stock worth $11,189,000 after buying an additional 471,290 shares in the last quarter. Delta Investment Management LLC acquired a new stake in MDxHealth during the fourth quarter worth about $81,000. Finally, FAS Wealth Partners Inc. grew its position in MDxHealth by 49.6% during the fourth quarter. FAS Wealth Partners Inc. now owns 24,425 shares of the company's stock worth $58,000 after buying an additional 8,100 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on MDXH shares. Wall Street Zen raised MDxHealth to a "hold" rating in a report on Saturday, May 24th. Craig Hallum started coverage on MDxHealth in a report on Thursday, July 17th. They set a "buy" rating and a $8.00 price objective on the stock. Three analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $7.00.

MDxHealth Trading Down 3.2%

MDXH stock traded down $0.12 during trading on Thursday, hitting $3.48. The company had a trading volume of 66,157 shares, compared to its average volume of 90,657. The company has a quick ratio of 1.22, a current ratio of 1.31 and a debt-to-equity ratio of 13.81. The firm has a 50-day moving average price of $2.52 and a 200-day moving average price of $2.02. MDxHealth SA has a 12 month low of $1.35 and a 12 month high of $3.81. The stock has a market cap of $164.33 million, a price-to-earnings ratio of -3.95 and a beta of 1.41.

MDxHealth (NASDAQ:MDXH - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). MDxHealth had a negative return on equity of 374.98% and a negative net margin of 34.98%.The company had revenue of $26.60 million during the quarter, compared to the consensus estimate of $26.60 million. MDxHealth has set its Q2 2025 guidance at -0.150--0.150 EPS. As a group, analysts predict that MDxHealth SA will post -1.15 earnings per share for the current year.

MDxHealth Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.